Immunicon Corp

Immunicon — Investor Presentation (May 2007)

29 slides from Immunicon's investor presentation, May 2, 2007

  1. Slide 1: Management Presentation May 2007

    Slide 1: Management Presentation May 2007

    Management Presentation May 2007 Cellular Information for Better Healthcare Circulating Tumor Cells Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation may contain forward-looking statements that reflect management ’ s current views and opinions as to the status of the Company ’ s products, clinical trials, regulatory approval process, product development, research programs and other future events and op

  3. Slide 3: Overview of Immunicon Corporation

    Slide 3: Overview of Immunicon Corporation

    Overview of Immunicon Corporation • IVD-cleared for monitoring metastatic breast cancer • Cancer cellular analysis products sold exclusively through Veridex

  4. Slide 4: Immunicon Value Proposition

    Slide 4: Immunicon Value Proposition

    Immunicon Value Proposition Immunicon develops and commercializes proprietary cell- and molecular- based human diagnostic and life science research products Cancer products sold through Veridex, a Johnson & Johnson company – Received FDA clearances for our instruments and CellSearch™ Circulating Tum

  5. Slide 5: CellTracks Products for Cellular Analysis

    Slide 5: CellTracks Products for Cellular Analysis

    CellTracks ® Products for Cellular Analysis Circulating Tumor Cell Kit Sample Collection and Preservation Standardized Rare Cell Capture Endothelial Cell Kit Sample Analysis Kits for Cell Counting

  6. Slide 6: Marker Reagents for Characterization for Targeted Therapy

    Slide 6: Marker Reagents for Characterization for Targeted Therapy

    Marker Reagents for Characterization for Targeted Therapy * HER-2/neu * EGFr * IGF-1R * bcl-2 * M30 * other candidates with Pharma Enrichment Kits for Downstream Molecular Analysis FISH in cartridge (in development) Cancer Confirmation Gene Amplification CEC Profile Kit Profile Kit CellTracks ® Prod

  7. Slide 7: Overview of Immunicon Pharma Services

    Slide 7: Overview of Immunicon Pharma Services

    Overview of Immunicon Pharma Services SM Assay development Protein biomarkers FISH probes New kits to capture, count and characterize rare cells Clinical Trial Testing Services CTCs as efficacy biomarker Protein or molecular biomarkers for mechanism Patient selection criterion to assign to appropria

  8. Slide 8: CellCapture

    Slide 8: CellCapture

    CellCapture™ CTC Mouse/Rat Kit Manually prepare samples/hour. Count CTCs with CellTracks ® Analyzer II.

  9. Slide 9: CTCs as a Real-Time Biopsy

    Slide 9: CTCs as a Real-Time Biopsy

    CTCs as a “ Real-Time Biopsy ” Blood Test Most tumors are of epithelial cell origin: Isolation of epithelial cells may mean pan-carcinoma capability Count Phenotype & Genotype Assess Prognosis Direct Therapy Monitor Disease Diagnose Specify Therapy Circulating Tumor Cells (CTCs) and Associated Marke

  10. Slide 10: Circulating Tumor Cells Predict Survival

    Slide 10: Circulating Tumor Cells Predict Survival

    Circulating Tumor Cells Predict Survival NEJM 2004, ASCO 2005, CellSearch package insert Time from Baseline (Months) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Logrank p < 0.0001 10.9 Months 21.9 Months <5 CTCs N=89 (50%) >5 CTCs N=88 (50%) Baseline CTCs Predict Outcome

  11. Slide 11: Change in CTCs Predict Survival

    Slide 11: Change in CTCs Predict Survival

    Change in CTCs Predict Survival 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Package Insert, December 2006 Clinical Cancer Research, July 2006 green vs. red p<0.0001 green vs. blue p=0.2023 green vs. orange p=0.0017 blue vs. red p<0.0001 N=83 22.6 mo. N=38 19.8 mo. N=17 10.6 mo. N=39 4.1 mo. Time from Bas

  12. Slide 12: Any CTCs Impact Survival: Treat to Zero!

    Slide 12: Any CTCs Impact Survival: Treat to Zero!

    Any CTCs Impact Survival: Treat to Zero! CTC / 7.5 ml blood Median 95% Low limit 95% Upper limit 29% 71% 61% 56% 51% 48% 45% 43% 43% 40% 36% =0 >1 >2 >3 >5 >7 >8 >9 >6 >4 >10 Median 95% Low limit 95% Upper limit =0 >1 >2 >3 >5 >7 >8 >9 >6 >4 >10 223 patients San Antonio Breast Cancer Symposium 2005

  13. Slide 13: A New Standard for Cancer Disease Management

    Slide 13: A New Standard for Cancer Disease Management

    A New Standard for Cancer Disease Management Future standard: Number, protein expression, and/or gene expression of CTCs better reflects efficacy of treatment Current standard: Radiologist measures changes in lesions on a CT scan to assess tumor burden increase/decrease Objective, quantitative 3-4 w

  14. Slide 14: Prediction of Outcome in Metastatic Breast Cancer

    Slide 14: Prediction of Outcome in Metastatic Breast Cancer

    CCR November 2006 / ASCO 2005 / Package Insert 2006 Prediction of Outcome in Metastatic Breast Cancer CTC @ ~4.6 weeks versus CT Scans @ ~11.9 weeks 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Time from Baseline (Months) 23.8 mo. Curve Logrank Comparison p-Value* vs. 2 0.1219 vs. 3 0.0400 1 vs. 4 <0.0001

  15. Slide 15: Personalized Medicine: Her2

    Slide 15: Personalized Medicine: Her2

    Her2 - Her2 + Her2 ++ Her2 +++ Time (weeks) Taxol Herceptin Int J Oncol 21: 1111-1118, 2002 “Personalized Medicine” Enables selection of targeted therapies

  16. Slide 16: Cancer Confirmatory Test

    Slide 16: Cancer Confirmatory Test

    Cancer Confirmatory Test Abnormal chromosome numbers are indicative of cancer Chromosome 1 Chromosome 7 Chromosome 8 Chromosome 17 Composite 3 copies 5 copies 4 copies 5 copies One CTC was detected in this patient with prostate cancer. FISH analysis revealed an abnormal number of chromosomes 1, 7, 8

  17. Slide 17: Assessment of Treatment Targets on CTCs

    Slide 17: Assessment of Treatment Targets on CTCs

    PNAS, 101: 9393-9398, 2004 Cytokeratin Her-2 Her-2 protein CEP 17 Her-2 gene CEP 17 / Her-2 gene 1+: 1.0 3+: 3.5 2+: 1.7 Assessment of Treatment Targets on CTCs

  18. Slide 18: Significant Clinical Utility of Circulating Tumor Cells

    Slide 18: Significant Clinical Utility of Circulating Tumor Cells

    Significant Clinical Utility of Circulating Tumor Cells Patient Management Early evidence of treatment failure: gives the oncologist information to change therapy within weeks Predictive at any time point during treatment CTCs predict survival time in patients undergoing chemo & hormonal therapy CTC

  19. Slide 19: EasyCount ViaSure Kit

    Slide 19: EasyCount ViaSure Kit

    Reports rapid, accurate total and live cell counts with % viability Simple to use Automation eliminates subjective interpretation associated with manual counting methods Uses proven technology EasyCount™ ViaSure™ Kit 24, 6-well slides + ViaSure™ Staining Reagent for 144 tests Cell Count and % Viabil

  20. Slide 20: Agreement with Diagnostic Hybrids, Inc.

    Slide 20: Agreement with Diagnostic Hybrids, Inc.

    Agreement with Diagnostic Hybrids, Inc. DHI funds IMMC R&D DHI conducts clinical trials and commercializes Revenue sharing Multiplex Respiratory Virus Panel Automated, reliable, and easy-to-interpret results with sensitivity close to gold standard cell culture assays and much faster. Patient managem

  21. Slide 21: Research and Clinical Development Programs

    Slide 21: Research and Clinical Development Programs

    Research and Clinical Development Programs Colorectal cancer – endpoints achieved! – 2Q07 FDA submission on 481 patient study Prostate cancer – endpoints achieved! – 2H07 FDA submission on 200+ patient study Research studies – CTCs in early stage breast cancer and colorectal cancer – Impact on survi

  22. Slide 22: Product Commercialization

    Slide 22: Product Commercialization

    Product Commercialization Oncologists Pathologists/ laboratories Pharma Services Molecular Diagnostics Products and Services Life Science Research Instruments and Kits Infectious Disease Diagnostics

  23. Slide 23: Summary of instrument shipments and sales

    Slide 23: Summary of instrument shipments and sales

    Summary of instrument shipments and sales Year ended Three months Cumulative @ March 31, 2007 March 31, 2007 Instrument shipments CellTracks Analyzer II CellS potter - Total Analyzers CellTracks AutoPreps Instruments sold (1) Total CellTracks Analyzer II Total CellS potter - Total Analyzers Total Ce

  24. Slide 24: System Placements, by Customer/Geography

    Slide 24: System Placements, by Customer/Geography

    System Placements, by Customer/Geography Third party: 73 CellTracks Analyzer II Upgrade 2.0 1.0 10.0 Veridex systems for internal use Pharma/CRO Reference Lab Hospital/Practice Total Systems Installed Total Japan/ Asia EU USA As of 3/31/2007

  25. Slide 25: Financial Status

    Slide 25: Financial Status

    Financial Status Cash burn guidance for 2007 - $16 to $18 million Product and service revenue guidance for 2007 - $11.75 to $14.5 million March 31, 2007 December 31, 2006 Cash and cash equivalents 46,808 $ 51,533 $ 3 months end 3/31/07 3 months end 3/31/06 Product & service revenue 2,554 $ 1,253 $ N

  26. Slide 26: Milestones Achieved

    Slide 26: Milestones Achieved

    Milestones Achieved Publications in major journals ( NEJM, CCR, JCO) 2004-2006 Trial in colorectal cancer – endpoints met Sep. 2006 510(k) clearance for MONITORING claims Dec. 2006 Trial in prostate cancer – endpoints met Jan. 2007 Expanded Kreatech license agreement for FISH Jan. 2007 Launched Easy

  27. Slide 27: Upcoming Milestones/Presentations

    Slide 27: Upcoming Milestones/Presentations

    Upcoming Milestones/Presentations Colorectal cancer 510(k)indication 2Q07 Prostate cancer 510(k)indication Scientific meetings – ASCO June 2007 – SABCS Dec. 2007 Expand rare cell FISH portfolio Expand Pharma Services business

  28. Slide 28: Immunicon Value Proposition

    Slide 28: Immunicon Value Proposition

    Immunicon Value Proposition Immunicon develops and commercializes proprietary cell- and molecular- based human diagnostic and life science research products Cancer products sold through Veridex, a Johnson & Johnson company – Received FDA clearances for our instruments and CellSearch™ Circulating Tum

  29. Slide 29: Contact Information

    Slide 29: Contact Information

    Contact Information 3401 Masons Mill Road, Suite 100 Huntingdon Valley, Pennsylvania 19006 phone 215.830.0777 fax 215.830.0751 web www.immunicon.com

Source: SEC EDGAR · 8-K filed May 2, 2007

More decks from Immunicon Corp